- Home
- NGNE vs NPCE Comparison
NGNE vs NPCE Comparison
Compare NGNE & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- NPCE
- Stock Information
- Founded
- NGNE 2003
- NPCE 1997
- Country
- NGNE United States
- NPCE United States
- Employees
- NGNE N/A
- NPCE N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- NPCE Medical Specialities
- Sector
- NGNE Health Care
- NPCE Health Care
- Exchange
- NGNE Nasdaq
- NPCE Nasdaq
- Market Cap
- NGNE 325.3M
- NPCE 292.9M
- IPO Year
- NGNE N/A
- NPCE 2021
- Fundamental
- Price
- NGNE $18.48
- NPCE $9.15
- Analyst Decision
- NGNE Strong Buy
- NPCE Strong Buy
- Analyst Count
- NGNE 7
- NPCE 6
- Target Price
- NGNE $41.86
- NPCE $16.67
- AVG Volume (30 Days)
- NGNE 110.1K
- NPCE 205.3K
- Earning Date
- NGNE 08-11-2025
- NPCE 08-12-2025
- Dividend Yield
- NGNE N/A
- NPCE N/A
- EPS Growth
- NGNE N/A
- NPCE N/A
- EPS
- NGNE N/A
- NPCE N/A
- Revenue
- NGNE N/A
- NPCE $88,570,000.00
- Revenue This Year
- NGNE N/A
- NPCE $22.13
- Revenue Next Year
- NGNE N/A
- NPCE $6.07
- P/E Ratio
- NGNE N/A
- NPCE N/A
- Revenue Growth
- NGNE N/A
- NPCE 23.32
- 52 Week Low
- NGNE $6.88
- NPCE $5.45
- 52 Week High
- NGNE $74.49
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- NPCE 51.74
- Support Level
- NGNE $19.59
- NPCE $8.61
- Resistance Level
- NGNE $20.46
- NPCE $8.99
- Average True Range (ATR)
- NGNE 1.23
- NPCE 0.53
- MACD
- NGNE -0.20
- NPCE 0.11
- Stochastic Oscillator
- NGNE 13.37
- NPCE 75.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.